LAS VEGAS, Oct. 2 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has retired a note, principal amount $160,000, in its continuing effort to reduce debt.
The convertible debenture was held by Tangiers Investors, LP, San Diego, California. "We told our stakeholders and potential investors that a major effort would be made throughout this year to reduce debt and strengthen our balance sheet. This is another example of fulfilling that commitment," said Matthew Schissler, co-founder and CEO.
Cord Blood America previously announced that, through August of 2009, it had reduced its secured debt by $6.6 million.
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America
Web Site: http://www.cordblood-america.com/
